CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.
CODA’s engineered receptors will be able to modulate the activity of virtually any cell in which the receptor is ectopically expressed, making them suitable for the treatment of many disorders. CODA can further tailor the therapy to a particular disease by simply changing the viral capsid, DNA regulatory elements, and route of administration.
CODA’s engineered receptors will be able to modulate the activity of virtually any cell in which the receptor is ectopically expressed, making them suitable for the treatment of many disorders. CODA can further tailor the therapy to a particular disease by simply changing the viral capsid, DNA regulatory elements, and route of administration.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $47M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | University... | innovation... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.12.2021 | - | $28M | - |
| 17.09.2018 | Series A | $19M | - |
Mentions in press and media 14
| Date | Title | Description |
| 06.12.2021 | Coda Biotherapeutics Raises $28M in Financing | Coda Biotherapeutics, a San Francisco CA-based preclinical-stage biopharmaceutical company, raised $28M in funding. The round was led by Pacira BioSciences, Inc. with participation from MPM Capital, Versant Ventures and Silicon Valley Bank ... |
| 03.12.2021 | Thank you | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. My fantastic Term Sheet readers: That’s right—today is my last day at Fortune, making this my las... |
| 03.12.2021 | Thank you | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. My fantastic Term Sheet readers: That’s right—today is my last day at Fortune, making this my las... |
| 02.12.2021 | CODA Biotherapeutics Closes $28 Million Financing led by Pacira BioSciences | SOUTH SAN FRANCISCO, Calif., Dec. 2, 2021 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders ... |
| 10.11.2020 | CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to Help Advance its Next-Generation Gene Therapy... | |
| 05.11.2019 | CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34M | - |
| 05.11.2019 | Coda Biotherapeutics is developing a cure for pain | If the researchers, executives and investors behind Coda Biotherapeutics have their way, one day soon there really could be a cure for pain. Co-founded by researchers Joseph Glorioso, from the University of Pittsburgh’s microbiology and mol... |
| 17.09.2018 | Coda Biotherapeutics Raises $19M in Series A Financing | Coda Biotherapeutics, Inc., a South San Francisco, Calif.-based preclinical-stage biopharmaceutical company developing a chemogenetic gene therapy platform for the treatment of intractable diseases, raised $19m in Series A financing. Lead i... |
| 14.09.2018 | Term Sheet — Friday, September 14 | BORING IS THE NEW BLACK Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop BORING IS GOOD? I can’t stop thinking about this NYT story by Farhad Manjoo, in which he explores the notion that i... |
| 13.09.2018 | Daily funding roundup - September 13th, 2018 | Applied Intuition has raised $11.5M; HYP3R raised $17M; Coda Biotherapeutics raised $19M Singularity 6: Singularity 6 explores new styles of game design and tackling difficult technical problems to create worlds that are beautiful and intri... |
Show more